There were significant treatment escalations ( new prescriptions or increased numbers of medicines ) for antiplatelet ( 17.9 % versus 2.7 % ; P < 0.001 ) , lipid-lowering ( 19.2 % versus 4.8 % ; P < 0.001 ) , and blood pressure-lowering medications ( 23.3 % versus 12.1 % ; P = 0.02 ) .